R.Ph.s give thumbs-down to Rx-to-OTC switch of Xenical
The majority of pharmacists are not in favor of an Rx-to-OTC switch of Roche’s antiobesity drug Xenical (orlistat), judging from the results of a recent Instant Poll on Drug Topics’ Web site. To the question “Should a weaker-strength version of Xenical be approved over the counter for weight loss?” 63% of the 224 respondents gave a thumbs-down to a switch, 35% voted in favor of it, and about 2% said they don’t know.
Recent Videos
Related Content
FDA’s Recent Exemptions: What Do They Mean as We Finalize DSCSA Implementation?
October 31st 2024Podcast
Kala Shankle, Vice President of Regulatory Affairs with the Healthcare Distribution Alliance, and Ilisa Bernstein, President of Bernstein Rx Solutions, LLC, discussed recent developments regarding the Drug Supply Chain Security Act.
